# OnCo record omidubicel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/omidubicel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "omidubicel" ;
  schema:name "Omidubicel"@en ;
  schema:description "An expanded umbilical cord blood graft that shortens the dangerous wait for neutrophils to return after a transplant for blood cancer, the first cell therapy approved to speed engraftment."@en ;
  schema:url <https://onco.cc/drugs/omidubicel/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell> ;
  onco:status "approved" ;
  onco:modality "Nicotinamide-expanded allogeneic cord blood cell therapy" ;
  schema:alternateName "Omisirge" ;
  onco:approval "US 2023: Adults and children aged 12 and over with haematologic malignancies undergoing umbilical cord blood transplantation after myeloablative conditioning, to reduce time to neutrophil recovery and infection" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/mds/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:companies <https://onco.cc/companies/gamida-cell/> ;
  onco:trials <https://onco.cc/trials/nct02730299/> .